Leming Pharmaceutical (Suzhou)
R&D of innovative transdermal drug delivery systems
About Leming Pharmaceutical (Suzhou)
Leming Pharmaceutical (Suzhou) Co., Ltd. is a high-tech pharmaceutical company founded in 2019, with its predecessor being Shanghai Lindmik Biotechnology Co., Ltd., established in 2001. The company, led by Chairman Mr. Gu Danhui, focuses on the research, development, production, and sales of innovative pharmaceutical preparations, with a specialization in transdermal drug delivery systems. Headquartered in Suzhou Wuzhong Biomedical Industrial Park, Leming also operates an R&D center in Beijing and has business development departments in the United States and Japan to manage the licensing of overseas projects.
The company has developed a technology platform that includes cataplasms (gel patches), tapes (hot-melt adhesive patches), and patches (solvent adhesive patches). Its business model combines in-house R&D with a "license-in" strategy to introduce advanced technologies like nano-based and microsphere drug delivery. Leming is preparing for a shift from being R&D-driven to full commercialization, with a production capacity of 500 million patches per year. Two of its core products, flurbiprofen gel paste and loxoprofen sodium gel paste, are in the late stages of regulatory review.
Leming has secured significant funding to support its growth and industrialization. A recent Series B funding round in June 2024 raised nearly 100 million yuan (approximately $13.8 million), led by CICC Private Equity and with participation from investors like Chengming Capital, Fuhui Venture Capital, and Ruihe Capital. This follows a Series A round in May 2023. The capital is intended to accelerate the development, production, and commercial launch of its core products. The company has established strategic partnerships with major pharmaceutical distributors like Kyushu Tong and Sinopharm Holdings to ensure broad market access upon product approval.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jun 2024 | $14M | $55M | Realharmony Capital · Chengming Capital · Fuho Capital · CICC | ↗ |
| SEEDEquity / VC | Sep 2021 | $0 | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Leming Pharmaceutical (Suzhou) is 2.4K monthly website visits, up 336.4% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Leming Pharmaceutical (Suzhou) in the Suzhou Shi ecosystem
The Leming Pharmaceutical (Suzhou) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
CICC- RCRealharmony Capital
- CCChengming Capital
- FCFuho Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Leming Pharmaceutical (Suzhou) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Leming Pharmaceutical (Suzhou)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








